Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
Currently, there is no medication available to adequately treat patients undergoing
hemodialysis who are suffering from intradialytic hypotension (IDH). Medical interventions
such as Trendelenburg positioning, saline bolus administration, reduction of ultrafiltration
rate, interruption of the hemodialysis, and other medical treatments are the methods of
choice to treat the hypotensive condition of these patients and thus to maintain the systolic
blood pressure. Patients suffering from IDH have a higher reported mortality rate due to the
given stress on their cardiovascular system. New treatments, therefore, would give clinicians
an additional alternative to current existing approaches and might help patients to maintain
their blood pressure during hemodialysis.
The main objective of the study is to evaluate the efficacy of icatibant in the prevention of
systolic blood pressure (SBP) drop in patients on hemodialysis suffering from recurrent IDH
episodes during hemodialysis.
Phase:
Phase 3
Details
Lead Sponsor:
Vanderbilt University Medical Center
Collaborators:
Pharvaris Netherlands B.V. Renal Research Institute